Immunovia AB (publ.) is a lean, focused diagnostic company seeking to revolutionize early detection of pancreatic cancer. We aim to improve outcomes for people at high risk of pancreatic cancer by detecting the disease at Stage 1 or 2 with our highly accurate blood test, PancreaSure. Immunovia plans to launch PancreaSure in the United States in the second half of 2025.
Immunovia was founded in Lund, Sweden based on protein research at Lund University. The company’s clinical lab and many of its employees are in the U.S.A., the company’s first commercial market.
Immunovia stock trades on the Nasdaq Stockholm exchange under the ticker symbol IMMNOV. Visit our website for more information.
Company Details
- Employees
- 23
- Founded
- -
- Address
- Medicon Village, Scheelevägen 2,sweden
- Phone
- +46-46-275 60 00
- in****@****via.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- immunovia.com
- Keywords
- Pancreatic cancer, Early diagnosis of cancer, Cancer therapy monitoring, Patient classification, Blood-based tests, Antibody microarray technology, Serum biomarker signatures, and Autoimmune diseases diagnosis, prognosis and therapy monitoring.
- HQ
- Lund
Immunovia Ab Questions
Immunovia Ab's helpline number is +46-46-275 60 00
Immunovia Ab's website is immunovia.com
Immunovia Ab's LinkedIn profile is https://se.linkedin.com/company/immunovia-ab
Immunovia Ab has
23 employees.
View email and phone details for 23
employees at Immunovia Ab.
Immunovia Ab's industry is
Biotechnology Research
Immunovia Ab's top competitors are
Genovis,
Alligator Bioscience Ab,
Camurus,
Bioglan Ab,
Sever Pharma Solutions,
Biogaia Ab,
Hansa Biopharma,
Rechon Life Science Ab,
Bioinvent International Ab,
Cantargia Ab.
Immunovia Ab's support email address is info@immunovia.com
Immunovia Ab's categories are Biotechnology Research
Immunovia Ab's founding year is 2007
